VIMIAN.ST
Vimian Group AB (publ) [VIMIAN.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VIMIAN.ST Stock Summary
Top 10 Correlated ETFs
VIMIAN.ST
Top 10 Correlated Stocks
VIMIAN.ST
In the News
VIMIAN.ST Financial details
Company Rating
Buy
Market Cap
16.61B
Income
-5.21M
Revenue
324.73M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1000
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
-216.15
Forward P/E
-
PEG
15.55
P/S
3.37
P/B
2.1
P/C
-
P/FCF
-30.28
Quick Ratio
0.61
Current Ratio
2.25
Debt / Equity
0.57
LT Debt / Equity
0.57
-
-
EPS (TTM)
-0.01
EPS next Y
-
EPS next Q
-
EPS this Y
-189.5%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
55.01%
Revenue last 5Y
103.29%
Revenue Q/Q
-1.76%
EPS Q/Q
100%
-
-
-
-
SMA20
3.23%
SMA50
14.29%
SMA100
33.33%
Inst Own
-
Inst Trans
-
ROA
-1%
ROE
-1%
ROC
0.06%
Gross Margin
69%
Oper. Margin
17%
Profit Margin
-2%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
20.08-37.96
52W High
-17.84%
52W Low
+52%
RSI
47
Rel Volume
0.53
Avg Volume
434.79K
Volume
232.26K
Perf Week
-6.61%
Perf Month
11.4%
Perf Quarter
32.46%
Perf Half Y
41.53%
-
-
-
-
Beta
1.518
-
-
Volatility
1.05%, 1.75%
Prev Close
-0.16%
Price
30.4
Change
-5%
VIMIAN.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0.06 | 5.55 | 0.5 | 0.7 | |
| Net income per share | 0 | 0 | 2.13 | 0.02 | -0.02 | |
| Operating cash flow per share | -0.01 | 0 | 0.19 | 0.05 | 0.06 | |
| Free cash flow per share | -0.01 | 0 | -0.03 | 0.01 | 0.04 | |
| Cash per share | 0 | 0.03 | 1.2 | 0.16 | 0.1 | |
| Book value per share | 0.05 | 0.11 | 9.03 | 1.02 | 1.2 | |
| Tangible book value per share | 0.01 | -0.01 | -3.22 | -0.34 | -0.46 | |
| Share holders equity per share | 0.05 | 0.11 | 9.03 | 1.02 | 1.2 | |
| Interest debt per share | 0.02 | 0.04 | 3.75 | 0.53 | 0.58 | |
| Market cap | 2.98B | 2.88B | 192.71M | 2.62B | 952.36M | |
| Enterprise value | 2.99B | 2.88B | 248.95M | 2.75B | 1.13B | |
| P/E ratio | -3.78K | -2.35K | 3.65 | 398.4 | -132.31 | |
| Price to sales ratio | 368.31 | 117.3 | 1.4 | 15.14 | 3.39 | |
| POCF ratio | -1.47K | 1.86K | 40.14 | 163.85 | 37.62 | |
| PFCF ratio | -1.3K | 6.16K | -243.01 | 580.25 | 63.47 | |
| P/B Ratio | 155.76 | 70.33 | 0.86 | 7.34 | 1.98 | |
| PTB ratio | 155.76 | 70.33 | 0.86 | 7.34 | 1.98 | |
| EV to sales | 368.95 | 117.44 | 1.81 | 15.86 | 4.02 | |
| Enterprise value over EBITDA | 3.79K | 709.92 | 3.04 | 67.08 | 17.06 | |
| EV to operating cash flow | -1.48K | 1.86K | 51.85 | 171.67 | 44.69 | |
| EV to free cash flow | -1.3K | 6.17K | -313.94 | 607.95 | 75.38 | |
| Earnings yield | 0 | 0 | 0.27 | 0 | -0.01 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0.02 | |
| Debt to equity | 0.35 | 0.38 | 0.38 | 0.5 | 0.46 | |
| Debt to assets | 0.2 | 0.16 | 0.19 | 0.28 | 0.24 | |
| Net debt to EBITDA | 6.6 | 0.84 | 0.69 | 3.06 | 2.7 | |
| Current ratio | 1.26 | 0.95 | 1.22 | 1.81 | 1.24 | |
| Interest coverage | -5.01 | 3.16 | 10.43 | 3.22 | 3.56 | |
| Income quality | 1.89 | -2.9 | 0.81 | 0.74 | 0.64 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.3 | 0.22 | 0.16 | 0.24 | 0.2 | |
| Research and developement to revenue | 0 | 0 | 0 | 0.01 | 0.03 | |
| Intangibles to total assets | 0.44 | 0.56 | 0.78 | 0.75 | 0.72 | |
| Capex to operating cash flow | 0.14 | -0.7 | -1.17 | -0.72 | -0.41 | |
| Capex to revenue | -0.03 | -0.04 | -0.04 | -0.07 | -0.04 | |
| Capex to depreciation | -0.41 | -0.39 | -0.8 | -0.69 | -0.38 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.05 | 0.09 | 20.78 | 0.66 | 0.69 | |
| ROIC | -0.03 | 0.02 | 0.21 | 0.02 | -0.43 | |
| Return on tangible assets | -0.04 | -0.03 | 0.52 | 0.04 | -0.03 | |
| Graham Net | -0.03 | -0.06 | -4.75 | -0.51 | -0.72 | |
| Working capital | 1.41M | -1.49M | 15.03M | 58.78M | 40.44M | |
| Tangible asset value | 5M | -3.74M | -79.94M | -120.31M | -186.87M | |
| Net current asset value | -6.91M | -20.63M | -98.28M | -150.6M | -235.37M | |
| Invested capital | 0.35 | 0.38 | 0.38 | 0.5 | 0.46 | |
| Average receivables | 10.5K | 5.16M | 20.11M | 36.65M | 73.67M | |
| Average payables | 886K | 2.51M | 7.05M | 12.07M | 15.81M | |
| Average inventory | 1.01M | 3.07M | 14.15M | 28.58M | 46.76M | |
| Days sales outstanding | 0.95 | 153.26 | 79.28 | 91.34 | 134.89 | |
| Days payables outstanding | 184.58 | 130.17 | 93.81 | 96 | 76.62 | |
| Days of inventory on hand | 210.1 | 165.03 | 209 | 238.34 | 253.07 | |
| Receivables turnover | 385.86 | 2.38 | 4.6 | 4 | 2.71 | |
| Payables turnover | 1.98 | 2.8 | 3.89 | 3.8 | 4.76 | |
| Inventory turnover | 1.74 | 2.21 | 1.75 | 1.53 | 1.44 | |
| ROE | -0.04 | -0.03 | 0.24 | 0.02 | -0.01 | |
| Capex per share | 0 | 0 | -0.23 | -0.03 | -0.03 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.17 | 0.2 | 0.18 | 0.17 | 0 | |
| Net income per share | -0.05 | 0.01 | 0.01 | 0.02 | 0 | |
| Operating cash flow per share | 0.05 | 0 | -0.13 | 0.03 | 0 | |
| Free cash flow per share | 0.04 | 0 | -0.13 | 0.02 | 0 | |
| Cash per share | 0.1 | 0.1 | 0.11 | 0.11 | 0 | |
| Book value per share | 1.09 | 1.17 | 1.14 | 1.17 | 0 | |
| Tangible book value per share | -0.42 | -0.47 | -0.44 | -0.41 | 0 | |
| Share holders equity per share | 1.09 | 1.17 | 1.14 | 1.17 | 0 | |
| Interest debt per share | 0.51 | 0.56 | 0.74 | 0.74 | 0 | |
| Market cap | 1.04B | 1.24B | 959.54M | 906.38M | 0 | |
| Enterprise value | 1.22B | 1.44B | 1.25B | 1.19B | -37.5M | |
| P/E ratio | -12.37 | 57.5 | 80.12 | 30.49 | 0 | |
| Price to sales ratio | 13.8 | 14.11 | 11.8 | 11.35 | 0 | |
| POCF ratio | 49.26 | 1.15K | -16.4 | 77.92 | 0 | |
| PFCF ratio | 58.27 | -632.61 | -15.57 | 94.86 | 0 | |
| P/B Ratio | 2.16 | 2.41 | 1.83 | 1.69 | 0 | |
| PTB ratio | 2.16 | 2.41 | 1.83 | 1.69 | 0 | |
| EV to sales | 16.17 | 16.3 | 15.35 | 14.96 | 0 | |
| Enterprise value over EBITDA | -152.27 | 56.09 | 67.75 | 65.67 | 0 | |
| EV to operating cash flow | 57.71 | 1.33K | -21.33 | 102.7 | 0 | |
| EV to free cash flow | 68.27 | -730.57 | -20.25 | 125.03 | 0 | |
| Earnings yield | -0.02 | 0 | 0 | 0.01 | 0 | |
| Free cash flow yield | 0.02 | 0 | -0.06 | 0.01 | 0 | |
| Debt to equity | 0.46 | 0.46 | 0.65 | 0.63 | 0.57 | |
| Debt to assets | 0.24 | 0.24 | 0.33 | 0.33 | 0.31 | |
| Net debt to EBITDA | -22.31 | 7.52 | 15.65 | 15.84 | 0 | |
| Current ratio | 1.24 | 1.32 | 2.65 | 2.25 | 2.12 | |
| Interest coverage | 8.59 | 1.95 | 0 | 0 | 0 | |
| Income quality | 1.85 | 0.06 | -5.77 | 1.17 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.16 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.11 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.72 | 0.72 | 0.71 | 0.71 | 0.74 | |
| Capex to operating cash flow | -0.15 | -2.82 | 0.05 | -0.18 | 0 | |
| Capex to revenue | -0.04 | -0.03 | -0.04 | -0.03 | 0 | |
| Capex to depreciation | -0.42 | -0.43 | -0.38 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.08 | 0.57 | 0.41 | 0.65 | 0 | |
| ROIC | 0.03 | 0.01 | 0.01 | 0.01 | 0 | |
| Return on tangible assets | -0.08 | 0.02 | 0.01 | 0.03 | 0 | |
| Graham Net | -0.66 | -0.84 | -0.8 | -0.78 | 0 | |
| Working capital | 40.44M | 57.26M | 150.26M | 101.92M | 84.04M | |
| Tangible asset value | -186.87M | -207.58M | -199.11M | -188.09M | -192.42M | |
| Net current asset value | -235.37M | -259.23M | -248.74M | -295.06M | -288.04M | |
| Invested capital | 0.46 | 0.46 | 0.65 | 0.63 | 0.57 | |
| Average receivables | 277.98M | 82.08M | 57.36M | 52.56M | 48.35M | |
| Average payables | 17.26M | 21.52M | 25.79M | 26.23M | 22.66M | |
| Average inventory | 61.44M | 62.53M | 65.85M | 67.7M | 64.26M | |
| Days sales outstanding | 124 | 61.5 | 60.36 | 57 | 0 | |
| Days payables outstanding | 70.03 | 81.74 | 97.71 | 88.59 | 0 | |
| Days of inventory on hand | 231.3 | 213.49 | 244.22 | 236.31 | 0 | |
| Receivables turnover | 0.73 | 1.46 | 1.49 | 1.58 | 0 | |
| Payables turnover | 1.29 | 1.1 | 0.92 | 1.02 | 0 | |
| Inventory turnover | 0.39 | 0.42 | 0.37 | 0.38 | 0 | |
| ROE | -0.04 | 0.01 | 0.01 | 0.01 | 0 | |
| Capex per share | -0.01 | -0.01 | -0.01 | 0 | 0 |
VIMIAN.ST Frequently Asked Questions
What is Vimian Group AB (publ) stock symbol ?
Vimian Group AB (publ) is a SE stock and trading under the symbol VIMIAN.ST
What is Vimian Group AB (publ) stock quote today ?
Vimian Group AB (publ) stock price is $30.4 today.
Is Vimian Group AB (publ) stock public?
Yes, Vimian Group AB (publ) is a publicly traded company.
Company Profile
- Volume Average 434.79K
- Market Capitalization 16.61B
- Employee 1000
- CEO Mr. Patrik Eriksson
- Headquarters Stockholm,SE
- IPO Date 2021-06-18
-
Website
https://vimian.com 
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.
